Bio-Techne Corp. Stock
Bio-Techne Corp. Stock
We can see a decrease in the price for Bio-Techne Corp.. Compared to yesterday it has lost -€1.000 (-1.820%).
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Bio-Techne Corp..
With a target price of 60 € there is a slightly positive potential of 11.11% for Bio-Techne Corp. compared to the current price of 54.0 €.
So far the community has only identified positive things for Bio-Techne Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Bio-Techne Corp. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Techne Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Techne Corp. | -1.820% | -7.563% | 8.911% | -24.658% | 10.000% | -26.667% | - |
| Icu Medical Inc. | 0.000% | -6.818% | -1.600% | -24.074% | -0.806% | -29.310% | -24.540% |
| Bio-Rad Labs Inc. A | 0.640% | -5.476% | -2.022% | -28.389% | -2.288% | -42.857% | -46.154% |
| Neogen Corp. | -1.720% | 0.000% | 38.525% | -23.874% | 37.398% | - | - |
Comments
Bio-Techne (NASDAQ:TECH) was given a new $72.00 price target on by analysts at Deutsche Bank Aktiengesellschaft. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Argus from $65.00 to $68.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at UBS Group AG from $65.00 to $70.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat